http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 31 Aug 2026 16:02:32 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/PMV+Pharmaceuticals+reports+46%25+response+rate+in+ovarian+cancer+trial/27005498.html <p>PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) released updated interim data from the Phase 2 portion of its PYNNACLE clinical trial, showing a 46% overall response rate in ovarian cancer patients treated with its experimental drug rezatapopt.</p><p>The data, cut off as of May 14, 2026, covered 76 patients with platinum-resistant or refractory ovarian cancer carrying a TP53 Y220C mutation. Of those patients, 35 responded to treatment, including four confirmed complete responses, 29 confirmed partial responses, and two unconfirmed partial responses, per investigator assessment using RECIST version 1.1 criteria.</p><p>The median time to response was 1.3 months, and the median duration of response was http://www.streetinsider.com/Corporate+News/PMV+Pharmaceuticals+reports+46%25+response+rate+in+ovarian+cancer+trial/27005498.html Mon, 31 Aug 2026 16:02:32 -0400 PMVP http://www.streetinsider.com/FDA/PMV+Pharmaceuticals+reports+46%25+response+rate+in+ovarian+cancer+trial/27005498.html <p>PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) released updated interim data from the Phase 2 portion of its PYNNACLE clinical trial, showing a 46% overall response rate in ovarian cancer patients treated with its experimental drug rezatapopt.</p><p>The data, cut off as of May 14, 2026, covered 76 patients with platinum-resistant or refractory ovarian cancer carrying a TP53 Y220C mutation. Of those patients, 35 responded to treatment, including four confirmed complete responses, 29 confirmed partial responses, and two unconfirmed partial responses, per investigator assessment using RECIST version 1.1 criteria.</p><p>The median time to response was 1.3 months, and the median duration of response was http://www.streetinsider.com/FDA/PMV+Pharmaceuticals+reports+46%25+response+rate+in+ovarian+cancer+trial/27005498.html Mon, 31 Aug 2026 16:02:32 -0400 PMVP http://www.streetinsider.com/Hot+Corp.+News/PMV+Pharmaceuticals+reports+46%25+response+rate+in+ovarian+cancer+trial/27005498.html <p>PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) released updated interim data from the Phase 2 portion of its PYNNACLE clinical trial, showing a 46% overall response rate in ovarian cancer patients treated with its experimental drug rezatapopt.</p><p>The data, cut off as of May 14, 2026, covered 76 patients with platinum-resistant or refractory ovarian cancer carrying a TP53 Y220C mutation. Of those patients, 35 responded to treatment, including four confirmed complete responses, 29 confirmed partial responses, and two unconfirmed partial responses, per investigator assessment using RECIST version 1.1 criteria.</p><p>The median time to response was 1.3 months, and the median duration of response was http://www.streetinsider.com/Hot+Corp.+News/PMV+Pharmaceuticals+reports+46%25+response+rate+in+ovarian+cancer+trial/27005498.html Mon, 31 Aug 2026 16:02:32 -0400 PMVP http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+30/26924840.html si-local-file:///var/storage/secattach/20260814/26924840.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+30/26924840.html Fri, 14 Aug 2026 08:02:00 -0400 O.22427321 PMVP http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+30/26924840.html si-local-file:///var/storage/secattach/20260814/26924840.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+30/26924840.html Fri, 14 Aug 2026 08:02:00 -0400 O.22427321 PMVP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PMV+Pharmaceuticals%2C++++++For%3A+Aug+14/26924812.html si-local-file:///var/storage/secattach/20260814/26924812.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PMV+Pharmaceuticals%2C++++++For%3A+Aug+14/26924812.html Fri, 14 Aug 2026 08:01:00 -0400 O.22427321 PMVP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PMV+Pharmaceuticals%2C++++++For%3A+Aug+14/26924812.html si-local-file:///var/storage/secattach/20260814/26924812.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PMV+Pharmaceuticals%2C++++++For%3A+Aug+14/26924812.html Fri, 14 Aug 2026 08:01:00 -0400 O.22427321 PMVP http://www.streetinsider.com/Press+Releases/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html <ul type="disc"><li style="text-align:justify;"><em>Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed</em><br/><br/></li><li style="text-align:justify;"><em>Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027</em><br/><br/></li><li style="text-align:justify;"><em>Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026 providing expected cash runway through second quarter of 2027</em><br/></li></ul> <p align="justify">PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results http://www.streetinsider.com/Press+Releases/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 O.20026344 O.22427321 PMVP http://www.streetinsider.com/Press+Releases/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html <ul type="disc"><li style="text-align:justify;"><em>Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed</em><br/><br/></li><li style="text-align:justify;"><em>Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027</em><br/><br/></li><li style="text-align:justify;"><em>Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026 providing expected cash runway through second quarter of 2027</em><br/></li></ul> <p align="justify">PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results http://www.streetinsider.com/Press+Releases/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 O.20026344 O.22427321 PMVP http://www.streetinsider.com/Press+Releases/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html <ul type="disc"><li style="text-align:justify;"><em>Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed</em><br/><br/></li><li style="text-align:justify;"><em>Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027</em><br/><br/></li><li style="text-align:justify;"><em>Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026 providing expected cash runway through second quarter of 2027</em><br/></li></ul> <p align="justify">PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results http://www.streetinsider.com/Press+Releases/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 O.20026344 O.22427321 PMVP http://www.streetinsider.com/Press+Releases/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html <ul type="disc"><li style="text-align:justify;"><em>Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed</em><br/><br/></li><li style="text-align:justify;"><em>Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027</em><br/><br/></li><li style="text-align:justify;"><em>Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026 providing expected cash runway through second quarter of 2027</em><br/></li></ul> <p align="justify">PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results http://www.streetinsider.com/Press+Releases/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 O.20026344 O.22427321 PMVP http://www.streetinsider.com/Globe+Newswire/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html <ul type="disc"><li style="text-align:justify;"><em>Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed</em><br/><br/></li><li style="text-align:justify;"><em>Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027</em><br/><br/></li><li style="text-align:justify;"><em>Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026 providing expected cash runway through second quarter of 2027</em><br/></li></ul> <p align="justify">PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results http://www.streetinsider.com/Globe+Newswire/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 O.20026344 O.22427321 PMVP http://www.streetinsider.com/Globe+Newswire/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html <ul type="disc"><li style="text-align:justify;"><em>Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed</em><br/><br/></li><li style="text-align:justify;"><em>Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027</em><br/><br/></li><li style="text-align:justify;"><em>Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026 providing expected cash runway through second quarter of 2027</em><br/></li></ul> <p align="justify">PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results http://www.streetinsider.com/Globe+Newswire/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 O.20026344 O.22427321 PMVP http://www.streetinsider.com/Globe+Newswire/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html <ul type="disc"><li style="text-align:justify;"><em>Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed</em><br/><br/></li><li style="text-align:justify;"><em>Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027</em><br/><br/></li><li style="text-align:justify;"><em>Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026 providing expected cash runway through second quarter of 2027</em><br/></li></ul> <p align="justify">PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results http://www.streetinsider.com/Globe+Newswire/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 O.20026344 O.22427321 PMVP http://www.streetinsider.com/Globe+Newswire/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html <ul type="disc"><li style="text-align:justify;"><em>Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed</em><br/><br/></li><li style="text-align:justify;"><em>Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027</em><br/><br/></li><li style="text-align:justify;"><em>Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026 providing expected cash runway through second quarter of 2027</em><br/></li></ul> <p align="justify">PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results http://www.streetinsider.com/Globe+Newswire/PMV+Pharmaceuticals+Reports+Second+Quarter+2026+Financial+Results+and+Corporate+Highlights/26924742.html Fri, 14 Aug 2026 08:00:00 -0400 A.06822034 O.20026344 O.22427321 PMVP http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PMV+Pharmaceuticals%2C+++++++++++++++++++Filed+by%3A+Sio+Capital+Management%2C+LLC/26828051.html si-local-file:///var/storage/secattach/20260728/26828051.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PMV+Pharmaceuticals%2C+++++++++++++++++++Filed+by%3A+Sio+Capital+Management%2C+LLC/26828051.html Tue, 28 Jul 2026 16:48:00 -0400 O.22427321 PMVP http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PMV+Pharmaceuticals%2C+++++++++++++++++++Filed+by%3A+Sio+Capital+Management%2C+LLC/26828051.html si-local-file:///var/storage/secattach/20260728/26828051.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PMV+Pharmaceuticals%2C+++++++++++++++++++Filed+by%3A+Sio+Capital+Management%2C+LLC/26828051.html Tue, 28 Jul 2026 16:48:00 -0400 O.22427321 PMVP http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PMV+Pharmaceuticals%2C+++++++++++++++++++Filed+by%3A+ArrowMark+Colorado+Holdings+LLC/26756330.html si-local-file:///var/storage/secattach/20260710/26756330.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PMV+Pharmaceuticals%2C+++++++++++++++++++Filed+by%3A+ArrowMark+Colorado+Holdings+LLC/26756330.html Fri, 10 Jul 2026 11:40:00 -0400 O.22427321 PMVP http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PMV+Pharmaceuticals%2C+++++++++++++++++++Filed+by%3A+ArrowMark+Colorado+Holdings+LLC/26756330.html si-local-file:///var/storage/secattach/20260710/26756330.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PMV+Pharmaceuticals%2C+++++++++++++++++++Filed+by%3A+ArrowMark+Colorado+Holdings+LLC/26756330.html Fri, 10 Jul 2026 11:40:00 -0400 O.22427321 PMVP http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Assumes+PMV+Pharmaceuticals+Inc.+%28PMVP%29+at+Buy/26743990.html <p>Ladenburg Thalmann assumes coverage on PMV Pharmaceuticals Inc. (NASDAQ: PMVP) with a Buy rating and a price target of $3.00.</p><p>For an analyst ratings summary and ratings history on PMV Pharmaceuticals Inc. <a href="http://www.streetinsider.com/rating_history.php?q=PMVP">click here</a>. For more ratings news on PMV Pharmaceuticals Inc. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=PMVP&amp;type=analyst">click here</a>.</p><p>Shares of PMV Pharmaceuticals Inc. closed at $1.24 yesterday.</p> http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Assumes+PMV+Pharmaceuticals+Inc.+%28PMVP%29+at+Buy/26743990.html Wed, 08 Jul 2026 06:39:58 -0400 PMVP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+04++Filed+by%3A+Stelzer+Laurie/26611633.html si-local-file:///var/storage/secattach/20260605/26611633.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+04++Filed+by%3A+Stelzer+Laurie/26611633.html Fri, 05 Jun 2026 16:33:00 -0400 O.22427321 PMVP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+04++Filed+by%3A+Stelzer+Laurie/26611633.html si-local-file:///var/storage/secattach/20260605/26611633.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+04++Filed+by%3A+Stelzer+Laurie/26611633.html Fri, 05 Jun 2026 16:33:00 -0400 O.22427321 PMVP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+04++Filed+by%3A+LEVINE+ARNOLD+J/26611540.html si-local-file:///var/storage/secattach/20260605/26611540.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+04++Filed+by%3A+LEVINE+ARNOLD+J/26611540.html Fri, 05 Jun 2026 16:31:00 -0400 O.22427321 PMVP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+04++Filed+by%3A+LEVINE+ARNOLD+J/26611540.html si-local-file:///var/storage/secattach/20260605/26611540.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+04++Filed+by%3A+LEVINE+ARNOLD+J/26611540.html Fri, 05 Jun 2026 16:31:00 -0400 O.22427321 PMVP http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+04++Filed+by%3A+Gallagher+Carol+Giltner/26611433.html si-local-file:///var/storage/secattach/20260605/26611433.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PMV+Pharmaceuticals%2C++++++For%3A+Jun+04++Filed+by%3A+Gallagher+Carol+Giltner/26611433.html Fri, 05 Jun 2026 16:25:00 -0400 O.22427321 PMVP